Aethlon Medical Inc. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment

Reuters
Sep 03
<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment

Aethlon Medical Inc. has announced the issuance of two patents related to the use of its Hemopurifier® for the treatment of Long COVID and COVID-19-associated coagulopathy $(CAC)$. U.S. Patent No. 12,409,260, which is set to be issued on September 9, 2025, covers the treatment of Long COVID by removing circulating COVID-19 spike protein in patients exhibiting symptoms for more than 12 weeks post-infection. Unitary European Patent 4136453, which was issued on July 9, 2025, pertains to the treatment of COVID-19-associated CAC in patients without circulating viral particles. These patents aim to strengthen the company's intellectual property portfolio in addressing significant unmet medical needs. The U.S. patent will expire in 2042, while the European patent will expire in 2041.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62338) on September 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10